Streetbeat News

Revenues

REG

Four analysts have recently published ratings on Regency Centers (NASDAQ:REG), showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $68.25, a decrease from the previous $72.00. Analyst actions include adjustments to ratings and price targets, reflecting changes in market conditions and company performance. Regency Centers, a leading retail REIT, reported a revenue growth of 14.34% and faces challenges in profitability and asset utilization, with a net margin of 24.02% and ROA of 0.7%.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:01 pm

CRI

Carter's (NYSE:CRI) has been the subject of varied analyst ratings over the past three months, with a recent shift towards a more bearish outlook. Despite this, the average 12-month price target for CRI has increased to $73.4, up from $67.80. Analysts from Citigroup, UBS, Evercore ISI Group, and Wedbush have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Carter's faces revenue challenges with a -5.95% decline over 3 months but maintains strong profitability indicators such as a net margin of 12.18% and ROE of 12.82%.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:00 pm

TXG

In the last three months, 4 analysts have updated their ratings on 10x Genomics (NASDAQ:TXG), showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $54.5, down from $57.00, indicating a 4.39% decrease. The company has seen a revenue growth of 17.76% as of December 31, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -26.61%, ROE of -6.59%, and ROA of -5.12%. Its debt-to-equity ratio is 0.13, suggesting a sound financial structure.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:00 pm

CMMB

Chemomab Therapeutics' stock price increased following the announcement of a new study that supports the clinical relevance of its CCL24 target in systemic sclerosis, linking it to disease severity and mortality.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:59 pm

LLY

NVO

The GLP-1 class of weight loss drugs, including Novo Nordisk's Wegvoy and Eli Lilly's Zepbound, are facing shortages expected to last until 2025 due to high demand. Eli Lilly's production delays are attributed to the overwhelming popularity of these drugs, with efforts underway to increase production at a new facility in North Carolina. Despite these efforts, limited availability of certain doses of Eli Lilly's drugs, including Mounjaro and Zepbound, is anticipated in the near term. Sales of these drugs surged to almost $11 billion in 2023, highlighting their significant impact on the market.

Portfolio Pulse from Vandana Singh

April 18, 2024 | 4:50 pm

AMZN

Amazon's stock has seen a significant rise, reaching a new high on April 11th and briefly surpassing its all-time peak from July 2021. With a 22% increase in 2024, the stock could potentially target the $200 mark if it breaks past its recent high. Amazon Web Services (AWS) continues to grow, nearly hitting a $100 billion annualized revenue run rate. First-quarter earnings predictions for Amazon are set at 83 cents a share on $142.6 billion in revenue, indicating a projected 11.6% sales growth. The stock's future momentum hinges on surpassing its previous all-time high, with a potential aim for the $200 level.

Portfolio Pulse from Zaheer Anwari

April 18, 2024 | 4:40 pm

LRLCY

L'Oreal reported a 9.4% like-for-like sales growth in Q1, reaching €11.24 billion. North America sales grew by 12.3% like-for-like, totaling €3.02 billion.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:04 pm

TECH

In the past three months, Bio-Techne (NASDAQ:TECH) received mixed analyst ratings, with a recent shift towards a more bullish outlook. The latest assessments show 1 bullish and 1 somewhat bullish rating, with 2 indifferent ratings previously. Analysts have adjusted their 12-month price targets for TECH, now averaging $77.25, down from $87.33, reflecting a more cautious view on the company's valuation. Despite this, Bio-Techne's financial performance remains strong, with notable revenue growth and net margin, though its ROE is below industry averages.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:01 pm

CVNA

A comprehensive review of 12 analyst recommendations for Carvana (NYSE:CVNA) reveals a mixed sentiment, with a notable shift towards a more positive outlook in recent months. The average 12-month price target for CVNA has increased by 34.98% to $69.58, indicating analysts' growing optimism. Despite this, Carvana faces challenges such as a -14.56% decline in revenue growth and below-average ROE and ROA, alongside a high debt-to-equity ratio. The analysis includes detailed actions and adjustments by key analysts from firms like JP Morgan, JMP Securities, and Morgan Stanley.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:01 pm

NIC

In the past three months, Nicolet Bankshares (NYSE:NIC) received four indifferent analyst ratings, with a shift towards a negative sentiment as the average 12-month price target was decreased by 1.37% to $87.12. Analysts from Stephens & Co. and Keefe, Bruyette & Woods, among others, adjusted their price targets and ratings, reflecting recent market dynamics and company performance. Nicolet Bankshares showcases strong financial health with a market capitalization above industry average, a revenue growth rate of 9.91%, and superior net margin and ROE compared to industry benchmarks.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:00 pm